Blackstone & TPG in $18B Hologic Takeover Shock – Women’s Health Stock Skyrockets
Hologic is a Marlborough, MA–based medical technology firm focused on women’s health. Its products include mammography and breast biopsy systems, cervical cancer tests, surgical equipment, and lab diagnostics including molecular tests for Covid-19 bostonglobe.com. The Blackstone/TPG consortium will buy all outstanding Hologic shares for $76 cash plus a $3 CVR marketscreener.com. This values the deal at $79 per share maximum and around $18.3 billion total enterprise value marketscreener.com. The purchase price represents a roughly 46% premium to Hologic’s share price before takeover rumors marketscreener.com. The agreement includes minority co-investments by ADIA and GIC, reflecting confidence from large sovereign investors. Goldman Sachs advised Hologic, while Citi and Bank of America advised Blackstone/TPG marketscreener.com. The transaction is expected to close in the first half of 2026, subject to approval by Hologic shareholders and regulators marketscreener.com. The Hologic board has unanimously recommended shareholders approve the merger agreement marketscreener.com. Following closing, Hologic will be delisted from Nasdaq and go private, though it will continue operating under the Hologic name with its Boston-area headquarters preserved marketscreener.com.